



## Biomarkers in Neurodegenerative Diseases

Guest Editor:

### Dr. Arnab Ghosh

Center for Gene Regulation in  
Health and Diseases, Department  
of Biological, Geological and  
Environmental Sciences,  
Cleveland State University,  
Cleveland, OH 44115, USA

Deadline for manuscript  
submissions:

**closed (28 February 2021)**

### Message from the Guest Editor

Dear colleagues,

Millions of people suffer from various neurodegenerative disorders worldwide, with a substantial rise in the number of new cases each year. Early diagnosis, accurate prognosis, and effective treatment management are needed to increase the quality of life for these patients. Recent technological advancements in proteomics, next-generation sequencing, immunological techniques, mass spectrometry, etc. have yielded significant mechanistic insights into these ailments. This Special Issue will focus on the current advancements of basic and clinical research that would lead to the identification, development, and application of new and improved biological markers for specific neurodegenerative diseases in the future. Both original research and comprehensive review are welcome.

Dr. Arnab Ghosh  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)